Novozymes enters collaboration with Solvay Pharmaceuticals  

The Danish enzyme manufacturer has entered a collaboration with Solvay Pharmaceuticals to develop new products for enzyme replacement therapy

Novozymes has entered a collaboration with the Belgium company Solvay Pharmaceuticals to develop new products for enzyme replacement therapy for patients suffering from pancreatic exocrine insufficiency (PEI). This condition, caused by diseases such as cystic fibrosis and chronic pancreatitis, means that patients have trouble digesting food and getting the proper nutrients from what they eat, which can lead to malnutrition.


The new products are expected to have an effect that is close to individual's own enzymes, which can improve current treatment. Novozymes is the world's leading enzyme manufacturer, while Solvay Pharmaceuticals leads the market for products for the treatment of PEI. The financial terms of the collaboration have not been disclosed, but according to Novozymes the agreement is expected to have a mildly positive effect on its operating profit for 2004 due to Solvay's payment of development costs.


Novozymes is headquartered in Bagsværd on the outskirts of Copenhagen. The company employs 3,900 people in 30 countries. Based on an advanced biotech platform, Novozymes produces and sells more than 500 enzyme products in 130 countries. The news is reported by Ritzau and on Novozymes' website.


Link > Novozymes 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×